Towards enhanced understanding of idiopathic ketotic hypoglycemia: a literature review and introduction of the patient organization, Ketotic Hypoglycemia International

Danielle Drachmann¹, Erica Hoffmann¹, Austin Carrigg¹, Beccie Davis-Yates¹², Valerie Weaver¹, Paul Thornton³, David A. Weinstein⁴, Jacob S. Petersen⁵, Pratik Shah⁶ and Henrik Thybo Christesen⁷⁸*

Abstract

Background: Idiopathic Ketotic hypoglycemia (IKH) is a diagnosis of exclusion. Although considered as the most frequent cause of hypoglycemia in childhood, little progress has been made to advance the understanding of IKH since the medical term was coined in 1964. We aimed to review the literature on ketotic hypoglycemia (KH) and introduce a novel patient organization, Ketotic Hypoglycemia International (KHI).

Results: IKH may be diagnosed after the exclusion of various metabolic and hormonal diseases with KH. Although often mild and self-limiting, more severe and long-lasting IKH occurs. We therefore divide IKH in physiological KH and pathological KH, the latter defined as recurrent symptomatic, or occasionally symptomatic, episodes with beta-hydroxybutyrate $\geq 1.0$ mmol/L and blood glucose < 70 mg/dL (3.9 mol/L), in the absence of prolonged fasting, acute infections and chronic diseases known to cause KH. Pathological KH may represent undiscovered diseases, e.g. glycogen storage disease IXa, Silver–Russel syndrome, and ketone transporter defects, or suggested novel disease entities identified by exome sequencing. The management of KH aims to prevent hypoglycemia, fatty acid oxidation and protein deficiency by supplying adequate amounts of carbohydrates and protein, including nutritional therapy, uncooked cornstarch, and sometimes continuous tube feeding by night. Still, intravenous dextrose may be needed in acute KH episodes. Failure to acknowledge that IKH can be more than normal variation may lead to undertreatment.

KHI is a non-profit, patient-centric, global organization established in 2020. The organization was created by adult IKH patients, patient family members, and volunteers. The mission of KHI is to enhance the understanding of IKH while advocating for patients, their families and the continued research into KH.

Conclusion: IKH is a heterogeneous disorder including physiological KH and pathological KH. IKH may represent missed diagnoses or novel disease entities, but shares common management principles to prevent fatty acid oxygenation. KHI, a novel patient organization, aims to enhance the understanding of IKH by supporting IKH families and research into IKH.
Introduction

Due to the lack of cerebral energy stores the brain depends on a continuous supply of glucose as a primary energy substrate. The brain is also capable of utilizing ketones, which occurs with fasting or chronic feeding of a high fat/low carbohydrate diet. The integration of metabolic pathways (glycogenolysis, gluconeogenesis, and fatty acid oxidation) and multiple counter-regulatory hormones (glucagon, epinephrine, growth hormone, and cortisol) combine to maintain normoglycemia. Hypoglycemia in children older than one month is uncommon, even in the setting of fasting. Ketosis during hypoglycemia, here referred to as ketotic hypoglycemia (KH), simply describes the physiologic changes (increased ketogenesis) which should occur in the setting of counter-regulation [1]. Despite more recent advances, only a minority of children with KH receive an endocrine or metabolic disorder diagnosis. The majority of KH patients are classically diagnosed as having “idiopathic” ketogenic hypoglycemia (IKH), also known as accelerated starvation. IKH is considered the most frequent cause of hypoglycemia in childhood [2–4]. Data about the incidence and prevalence of KH and IKH are missing, but KH is the most common diagnosis applied to episodes of hypoglycemia in children in emergency departments in the US [2, 3]. While IKH is currently defined as a collective set of symptoms not related to an underlying pathology, severe IKH might still be considered as a rare disease entity in and of itself. A search of Orphanet for “idiopathic ketotic hypoglycemia” and “ketotic hypoglycemia” yielded neither an Orpha number, an Online Mendelian Inheritance in Man (OMIM) gene- or phenotype reference number, nor an ICD-10 number. IKH is referenced in the Human Phenotype Ontology (HPO) as HP:0012734, a sign of other known rare diseases [5, 6].

Little progress has been made to advance the understanding of IKH since 1964, where unexplained KH was reported in eight children after exclusion of hormonal and metabolic diseases [7]. IKH has been considered by some as a non-pathological condition in infants, representing the lower tail of the Gaussian normal distribution for fasting tolerance [8]. However, some children with unexplained KH, or IKH, are more severely affected and do not go into remission before school age and may even have IKH in adulthood. Such individuals had not had a patient organization with which to gain support, scientific information or research data, and currently do not have any standardized clinical management guidelines to follow. The aim of this paper is to review the literature on KH and introduce a novel patient organization, Ketotic Hypoglycemia International (KHI). Because much of the research available is centered on the pediatric population, this paper focuses solely on IKH in children.

Metabolism of glucose, fats and ketones

In healthy individuals maintenance of stable plasma glucose (PG) concentration is easily performed by the body’s neuroendocrine and metabolic defenses, and potential consequences from prolonged fasting are low. However, a disproportionate balance between cellular glucose entry and glucose outflow secondary to deficient delivery of glucose into circulation, excessive glucose removal from circulation, or both, will place the body in a state of hypoglycemia [9, 10]. While glucose entry from the blood to the brain neurons and to liver cells is dependent on glucose concentration gradients, most other tissues (primarily muscle tissue) are dependent on insulin for glucose entry to the cells. As PG begins to fall, the pancreas stops producing insulin and decreases the amount of glucose available to most tissues, with the exception of the brain.

If the PG continues to fall, the counter-regulatory hormones glucagon, cortisol, growth hormone, epinephrine (adrenaline) and norepinephrine (noradrenaline) are released into circulation, and the breakdown of triglycerides to glycerol and fatty acids in the adipocytes (lipolysis) occurs, Fig. 1 [10–12]. The glycerol is then converted to glucose in the liver (gluconeogenesis). Both glycerol and amino acids serve as substrates for glucose production in the hormonally controlled gluconeogenesis. The free fatty acids from lipolysis are processed by liver cell mitochondria into acetoacetate (AcAc), beta-hydroxybutyrate (BOHB), and, to a lesser degree, acetone, which together are named ketone bodies. These ketone bodies are an alternative source of energy for the brain and muscles when glucose is unavailable [13, 14].

Fuel production in infants and children is similar to that of adults; however, due to their larger brain size in proportion to their body weight, PG concentrations in infants and children drop more rapidly and elevated ketone body levels (hyperketonemia) develop sooner [10, 13]. The brain has back-up stores of fuel in the form of glycogen to compensate for low PG levels [14–16]. These glycogen stores only last a few minutes, so individuals that cannot regulate their PG levels are at risk for interruption of glucose delivery to the brain, putting them in danger of devastating consequences. Recovery is usually

Keywords: Idiopathic ketogenic hypoglycemia, Children, Glycogen storage disease, Rare disease, Ketone bodies, Hypoglycemia
complete from short-lived episodes of hypoglycemia, though prolonged and severe hypoglycemia can cause permanent brain damage [14, 17–19].

**Ketosis**

Ketone bodies can protect the brain from damage by providing an alternate fuel source. Ketones provide 2–6% of the body’s energy requirements after an overnight fast and up to two-thirds of the brain’s energy needs after a prolonged fast or during starvation [13, 14]. Normal infants and children can also develop hyperketonemia during illness, after bouts of vomiting or diarrhea, or after prolonged fast with an inverse relation to age [20–24].

The normal serum concentration of ketones measured as 3-BOHB is assay-dependent, but invariably given as < 0.6 mmol/L [25, 26]. Hyperketonemia is most often defined as BOHB concentrations between 1.0 and 3.0 mmol/L [25]. This definition reflects to the authors’ clinical experience the threshold of symptomatic ketosis, which begins around 1.0 mmol/L.

Ketoacidosis is defined as BOHB > 3.0 mmol/L with resultant metabolic acidosis [25, 26]. The metabolic acidosis occurs as the rapid rise in ketone bodies and subsequent saturation of skeletal muscle uptake mechanisms causes an increase in serum hydrogen ion concentration that overwhelms the body’s natural buffering system [25]. In studies with prolonged fasting in healthy controls, the 90th percentile of BOHB reached 1.0 mmol/L after 15 h fast in 1–12 months old infants; 0.9 mmol/L at age 1–7 year; and 0.3 mmol/L at age 7–15 years [22]. The 97.5th percentile of BOHB after 14 h fast was 1.5 mmol/L in 3-y-olds; 0.7 mmol/L at age 9 years; and after 40 h fast 8.9 mmol/L at age 6–11 years [23, 24].

In the acute phase, high ketones can cause nausea, vomiting, abdominal pain, muscle cramps, headache, lethargy, and at its most severe, coma and polypnea (Kussmaul breathing) [3, 26]. Acetone excretion by the lungs results in a characteristic aromatic smell on the breath. If measures are not taken to arrest ketogenesis and flush out excess ketones from the body, ketoacidosis can develop, constituting a need for emergent intervention [25]. Chronic ketosis can result in poor growth, hepatic transaminase elevation, and osteoporosis [27].

**Diagnosis of ketotic hypoglycemia**

**Definition of KH and IKH**

IKH has long been considered the lower end of normal variation for fasting tolerance in infants [8] However, IKH seems to represent a broad clinical spectrum from occasional mild KH in infancy to severe and more long-lasting KH, sometimes with other clinical or biochemical manifestations. We propose that IKH be split into physiological KH and pathological KH. We define pathological KH as recurrent symptomatic, or occasionally symptomatic, episodes with BOHB \(\geq\) 1.0 mmol/L and blood glucose < 70 mg/dL (3.9 mmol/L), in the absence of prolonged fasting, acute infections and chronic diseases known to cause KH. This definition allows for episodes with euglycemic hyperketosis.

Physiological KH is most commonly seen in normal children with intercurrent acute illness causing prolonged starvation and increased metabolism due to fever. Moreover, KH may be frequent in conditions with excess starving or malnutrition. In a few studies, KH was reportedly common in African children with chronic malnutrition or severe malaria [28, 29].

Pathological forms of KH are seen in children with deficiencies in the counter regulatory hormones such as cortisol or growth hormone, or in metabolic conditions
such as glycogen storage disease (GSD, specifically GSD 0, III, VI, and IX), disorders of ketone transport and ketone utilization, and defects in protein metabolism, Table 1 [30, 31]. Specific syndromes with KH should be identified, e.g. Silver–Russell syndrome where more than one in four have KH after a simple overnight fast [32, 33].

IKH may be diagnosed when all the above causes have been excluded. Because there may be many yet undiscovered specific etiologies for IKH, it can be considered as a condition with disturbed glucose homeostasis, the cause being failure of meaningful hepatic gluconeogenesis rather than an accelerated glucose oxidation rate [9, 31, 34]. In keeping, hypoaalaninemia has been found in children with KH compared to age-matched controls [35]. The body’s inability for self-regulation results in a state of low PG levels with elevated ketones and various outward signs and symptoms shown by the child.

No uniform diagnostic criteria for PG or ketone body concentrations have been established for the diagnosis of KH. Hypoglycemia in adults and children cannot be defined by a single PG cut-off [13, 36]. van Veen et al. found that children below 2 years had physiological KH

| Table 1 Causes to ketotic hypoglycemia in children |
|---------------------------------------------------|
| **Gene or chromosome** | **Inheritance** |
|------------------------|----------------|
| **Hormonal**           |                |
| Growth hormone deficiency, or resistance          | Genetic or acquired | Variable |
| ACTH deficiency or resistance; cortisol deficiency| Genetic or acquired | Variable |
| Glucagon deficiency*                                      | GCG, DBH          | N/D      |
| Dopamine beta-hydroxylase deficiency*              | GCG, DBH          | N/D      |
| **Metabolic**                           |                |
| Glycogen storage disease (GSD)                    |                |
| GSD 0; glycogen synthase deficiency              | GYS2             | AR       |
| GSD III; glycogen debranching enzyme deficiency  | AGL              | AR       |
| GSD VI; glycogen phosphorylase deficiency        | PYGL             | AR       |
| GSD IX; phosphorylase kinase subunit deficiencies | PHKA2, PHKB, PHKG2 | X-linked, AR |
| Glucose metabolism and transport                 |                |
| Phosphoglucomutase I deficiency                  | PMG1             | AR       |
| Pyruvate carboxylase deficiency                  | PC               | AR       |
| Organic acidemias                                 |                |
| Maple syrup urine disease, propionic aciduria, methylmalonic aciduria | Multiple genes | AR |
| **Ketone body transport and metabolism**          |                |
| Monocarboxylase transporter 1 defect             | SLC16A1 (MCT1)   | AR,AD    |
| Ketolysis                                         |                |
| Succinyl CoA oxoacid transferase deficiency      | SCOT             | AR       |
| Mitochondrial acetoacetyl-CoA thiolase (beta-ketothiolase) deficiency | ACAT1         | AR       |
| **Syndromes**                                     |                |
| Silver–Russel syndrome                           | 11p15 or 7**     | Mostly sporadic |
| Prader–Willi syndrome                            | 15q11-q13***    | Mostly sporadic |
| Fanconi–Bickel syndrome                          | SLC2A2 (GLUT2)   | AR       |
| Secondary KH to chronic malnutrition, severe malaria, other chronic diseases | - | - |
| Idiopathic ketotic hypoglycemia                   |                |
| Physiological KH in prolonged fasting or acute illness | - | - |
| Pathological KH                                   |                |
| IGF2BP1 deficiency*                              | IGF2BP1          | N/D      |
| Sodium glucose co-transporter 2 defect*           | SLC5A2           | N/D      |
| PEP carboxykinase 1 and G-6P catalytic transcriptional induction* | NCO1         | N/D      |
| Mitosis gene A-related kinase 11 defect*          | NEK11            | N/D      |

AD: autosomal dominant, AR: autosomal recessive, N/D: no data, PEP: phosphoenolpyruvate, G-6P: glucose 6-phosphate. The list is not fully inclusive

* Suggested, not well-established causes to KH
** Several mechanisms, rare other mechanisms, or unknown
*** Paternal deletion, maternal uniparental disomy, or imprinting defect
with PG below 70 mg/dL (3.9 mmol/L) and hyperketonemia after fasting for 15 h or shorter [21]. This study, however, included children with potential pathological KH.

In children with the diagnosis of IKH, hyperketonemia with euglycemia appears to occur more frequent than hyperketonemia with hypoglycemia [26]. In the author’s experience (HTC), this may, however, be the result of non-recorded nocturnal hypoglycemia as demonstrated with continuous glucose monitoring (CGM).

The demonstration of Whipple’s triad for hypoglycemia (symptoms and signs, low PG and relief of symptoms and signs after normalization of PG) is often used to support the diagnosis of hypoglycemia, but is not straightforward in KH. Symptoms are difficult to read in infants and recurrent hypoglycemia leads to hypoglycemia-associated autonomic failure with blunting of the autonomic symptoms of hypoglycemia, which results in hypoglycemia unawareness, irrespective of age [37, 38]. The clinical picture of IKH is described below.

**Clinical picture of IKH**

Episodes of KH are usually seen from around 6 months’ age, with the hypoglycemia attributed to poor oral intake or illness [3, 9, 39]. In a series of 62 children with KH, 29% had, however, no history of a precipitating event that could explain the hypoglycemia [40]. To the authors’ experience, increased physical activity and poor food intake the day before can be identified in a higher number of patients after detailed evaluation at the time of a KH event.

Remission of IKH is classically thought to occur between 6–7 years of age when children have increased their muscle mass and decreased their glucose requirement per unit of body mass [40, 41]. In some patients, episodes of KH may persist past puberty into adulthood, and family investigations may reveal parents with a history of KH [42]. This should prompt further diagnostic investigations and be regarded as pathological KH.

Children with KH may exhibit a wide range of symptoms and signs. Younger children cannot be relied upon to accurately recognize and communicate symptoms of hypoglycemia [13, 37, 38, 43–45]. It is often up to the primary caregiver(s) to interpret whether the child is experiencing a hypoglycemic event and if intervention is warranted. Episodes frequently occur in the morning after an overnight fast (10–12 h). In response to the hypoglycemic state overnight, ketone development has already begun, making management of symptoms a challenge for caregivers [40].

Symptoms and signs of the combination of hyperketosis and hypoglycemia in KH include nausea, abdominal pain, vomiting, headache, lethargy, pallor, sweating, tremors, muscle cramps, visual/sensory disturbances, speech difficulty, mental confusion, bizarre behavior (such as crying for no reason), temper tantrums, restlessness, personality changes, seizures and coma [3, 7, 14, 26, 40, 41]. The presence of neuroglycopenic symptoms despite the brain-protective hyperketonemia may suggest a ketone utilization or ketone transport defect in these patients. What makes KH particularly complex is that some of the symptoms, such as muscle cramps, headache and abdominal pain, may result from either hypoglycemia or hyperketonemia.

Some children with IKH are small and thin for their age, with minimal fat deposits or muscle development [41]. Such children have little to no tolerance for fasting and often display poor eating habits. The poor appetite may be caused by hyperketonemia, inducing a vicious cycle provoking further KH.

**Diagnostic procedures in IKH**

If the KH is not investigated during a spontaneous acute episode with severe symptoms and signs, a controlled fasting test in the hospital setting can help to establish the KH diagnosis and to give an impression of its severity. Dependent on age, an overnight fasting study can be performed until the glucose is either <50 mg/dl (2.8 mmol/L) or the BOHB is >2 mmol/L. At the end of the fasting study, a diagnostic critical sample is obtained. A controlled fasting study with frequent monitoring of both glucose and BOHB allows the physician to identify when the BOHB rises above 1 mmol/L and thus gives the family an understanding of the child’s fasting tolerance. Permanent or excessive ketosis should lead to investigations for ketone transporter or utilization defects.

Once the diagnosis of IKH is established, the frequency and severity of KH should be determined as part of the initial work up. Home monitoring with point of care (POC) meters with testing for glucose and ketones should be performed, particularly on waking in the morning or with symptoms until a true pattern emerges. CGM may be helpful, but are not rigorously studied in IKH and cannot stand alone due to inaccuracy at lower glucose levels. The episodical nature of KH may call for prolonged home monitoring in pathological KH (see also the Management section below).

Patients with pathological KH represent a diagnostic challenge to physicians and caretakers. Pathological KH with or without atypical manifestations should lead to expanded diagnostic procedures. A clinical example is given in Table 2.

**Search of new causes to KH**

A predominance of IKH in males has been reported [3, 40]. This may suggest an unrecognized disease on the X-chromosome such as GSD IXa in these children.
Indeed, several patients diagnosed with KH or IKH have been found to have mutations in *PHKA2* [30, 40, 46]. By use of trio exome sequencing, research has identified mutations not only in *PHKA2*, but also in *SLC16A1* (MCT1), *NCOR1, IGF2BP1, SGLT2* and *NEK11* as (potential) novel causes of more atypical children with otherwise unexplained KH [42, 47].

*SLC16A1* codes for monocarboxylate transporter 1 (MCT1), which mediates transport of pyruvate, lactate and ketone bodies across cell membranes. Patients with heterozygous or homozygous inhibiting mutations in *SLC16A1* presented with moderate or profound ketosis and sometimes hypoglycemia at fasting or during infections, with onset in the first years of life [40, 47, 48]. In some of the patients, migraine, exercise intolerance, developmental delay, microcephaly and abnormal MRI of the brain were noted.

The study of Alhaidan et al. identified predicted disease-causing heterozygous DNA variants in *NCOR1, IGF2BP1, SGLT2* and *NEK11*, respectively, in four children with otherwise unexplained KH [42]. The *NCOR1/HDAC3* complex is involved in the regulation of liver phosphoenolpyruvate carboxykinase 1 (PCK1), glucose 6-phosphatase catalytic (G6PC) and hepcidin. The KH patient with an *NCOR1* mutation had loose stools and iron deficiency anemia as additional features, the latter possibly caused by hepcidin overexpression. Of note, G6PC homozygous mutations leads to GSD Ia with non-ketotic hypoglycemia, hepatomegaly and iron deficiency [49].

*IGF2BP1* (not to be confused with *IGFBP1*) is a sparsely described translational regulator of several proteins, including IGF2, which is involved in cell growth and differentiation and activates the insulin receptor. Patients with IGF2-producing tumors have impaired glycogenolysis and gluconeogenesis with hypoglycemia and suppressed insulin secretion [50–52]. The KH patient with a heterozygous *IGFBP1* mutation had short stature and retarded bone age without identifiable defects in the growth hormone axis as additional features.

Heterozygous mutations in *SLC5A2*, which encodes the sodium glucose co-transporter 2 (SGLT2), cause familial renal glucosuria (FRG) [53]. The KH patient with a heterozygous *SLC5A2* mutation had intermittent glucosuria, rapid clearance of glucose and drastically increased fasting p-GLP1 as additional features, suggesting KH in infancy as a novel manifestation of FRG.

The mitosis gene A-related kinase 11 gene *NEK2* has not been linked to other diseases in humans than KH. In a heterozygous *NEK11* mutation mouse model, a significant reduction in glucose levels was the only reported feature [54]. The KH patient with a heterozygous *NEK11* mutation had recurrent migraine, cognitive and motor deficits, mild liver affection, absent glucose response to i.m. glucagon and decreased p-IGFBP3 as additional features.

A number of children with pathological KH remains unexplained despite trio exome sequencing [42]. Pathological KH may well represent a disease entity with several different unidentified monogenetic, digenic, polygenic, or epigenetic causes [12, 30]. A case report with KH in one, but not the other homozygotic twin illustrates the complexity of KH [55].

**Management of idiopathic ketotic hypoglycemia**

The monitoring and treatment of children with IKH should be individualized according to severity, frequency and response. While physiological KH only will need attention in case of acute illness or prolonged fasting, pathological KH may need everyday monitoring and treatment. Common management principles for pathological KH are presented in Table 3. POC glucometers have different diagnostic performances and are less reliable in the lower range [56–58]. Moreover, finger prick
capillary PG concentrations derive from the optimal venous PG concentration, and the automatic 1.1 conversion factor from whole blood POC glucometers to report PG concentrations may not reflect the actual erythrocyte volume fraction of an infant. Despite these limitations, home monitoring with POC testing for PG and ketones should be used in monitoring KH in its severe forms. POCT for blood BOHB should be preferred from the less precise urine stix AcAc [59].

As the frequency and severity of KH episodes vary, the need for home monitoring must be individualized for each patient. Severely affected children may benefit from CGM, although low glucose values or decreasing trend alarms should be controlled with a glucometer to improve precision. As hyperketonemia may be of clinical significance without simultaneous hypoglycemia, blood ketone monitoring may be recommended for normoglycemic patients exhibiting signs and symptoms of illness.

POC monitoring may be an economic burden on the family, as well as a logistical challenge for custodial daycare and school personnel. On the other hand, POC testing may facilitate the correct identification of episodic behavioral changes as symptoms of KH instead of general “bad behavior”, psychosocial reactions, or ADHD, which had occurred according to the anecdotal experience in the new patient organization, KHI. Still, the need of monitoring should be evaluated regularly to avoid both “over” and “under”-monitoring.

The Pediatric Endocrine Society recommends maintaining a PG concentration of > 70 mg/dL (3.9 mmol/L) as goal of treatment for hypoglycemia in infants and children, however allowing for an individualized, tailored approach to management [13]. To the authors’ experience, children with pathological KH benefit from an individualized PG goal to keep BOHB < 1.0 mmol/L. This may fit with a PG kept > 70 mg/dL (3.9 mmol/L), but an individual PG goal for each child to avoid hyperketosis should be determined in the diagnostic process.

Nutritional therapy, avoidance of prolonged fasting, increased frequency of feedings, and close monitoring of oral intake, especially in times of stress or high activity, are suggested to mitigate episodes of hypoglycemia [12, 13]. Uncooked cornstarch has been used to extend the times between feedings by delaying onset of hypoglycemia. Traditional cornstarch has been used for 40 years to prevent nocturnal hypoglycemia, with the measured length of time for digestion being 3–4 h [27, 60].

For some children with pathological KH, as in those with KH due to GSD I, an overnight administration of cornstarch is necessary. In addition to cornstarch therapy, children with pathological KH that are unable to maintain fasting for any significant length of time may be evaluated for gastrostomy tubes for bolus or continuous

Table 3 Management of pathological KH in children

| Monitoring                        | Range of use                                                                 |
|----------------------------------|-----------------------------------------------------------------------------|
| Bedside glucometer and blood ketones | Initial work up; Fever, vomiting or diarrhea; at symptoms/morning fasting values/frequent daily |
| Continuous glucose monitoring*   | Initial work up; for months or years in more severe, pathological KH        |

Prevention

Dietary

| Complex carbohydrates, protein   | Before sleep only; for every meal                                           |
| Meal interval                    | Dependent on age, severity and frequency of KH                             |
| Uncooked corn starch             | ½–1 (≈2) g/kg, 1–4 x daily                                                 |
| Long-release corn starch         | Severe, frequent KH                                                        |
| Continuous gastrostomy tube feeding | Severe, frequent KH. Night feeding with maltose 1/2–1 g/kg/h; other tube feeding products |

Acute treatment

Dietary

| Sugar-rich drinks and food       | KH attacks without compromised swallowing. Add complex carbohydrates, eventual protein |
| Buccal carbohydrate gel application | KH attacks with compromised swallowing. 1/2–1 tube, eventually repeated |

Medication

| I.m. glucagon                    | Severe KH attacks with unconsciousness. 30–40 mcg/kg, maximal 1 mg. Only if proven efficient and safe at specialist center |
| I.v. glucose or dextrose         | Severe KH attack. Ensure PG > 3.9 mmol/L (70 mg/dL). Continue until blood ketones < 0.5 mmol/L |

KH: ketotic hypoglycemia, PG: plasma glucose

*Continuous glucose monitoring cannot stand alone due to inaccuracy at low glucose concentrations, and needs further research specifically in KH
tube feedings [27, 60]. Protein-rich diet or dietary products should be considered if low protein or prealbumin concentrations are documented. Proteins provide substrate for gluconeogenesis and may reduce muscle cramps associated to KH.

Nausea and vomiting caused by ketones may lead to further decline in PG if hyperketosis is not recognized and treated. The acute treatment principle includes administration of high glycemic index (i.e. dextrose-rich) foods or drinks to provide energy from glucose metabolism instead of fatty acid metabolism which leads to further ketone body formation.

If hypoglycemia is unable to be corrected or the child becomes increasingly unresponsive, emergency intervention should be sought. Buccal carbohydrate gel administration, intravenous (IV) dextrose or intramuscular glucagon (if proven effective and safe by formal testing) may be administered to raise PG concentrations to $\geq 70$ mg/dL (3.9 mmol/L). Of note, some patients with IKH have a normal i.m. glucagon response without provoking lactate acidosis, unlike the response in those with GSD I [3, 35, 39].

Elimination of ketones can take hours, and if the child is in an acidotic state, IV fluid therapy may be needed to return the patient to homeostasis. Intravenous dextrose can help to stop ketogenesis and lipolysis, and rehydration assists in renal excretion of ketones [12, 25, 41]. A better understanding of KH through identification of novel genetic causes may help physicians to target the treatment of children with pathological KH.

**Ketotic Hypoglycemia International**

Established in January, 2020, Ketotic Hypoglycemia International (KHI) is a new, worldwide patient organization for families affected by idiopathic ketotic hypoglycemia (IKH). Our scientific advisory board and organization board of directors are volunteers. The mission of KHI is to enhance the understanding of IKH for the benefit of children, parents, and families who have been affected by IKH. KHI aims to support patients and their families by sharing knowledge about IKH, and to support the continued research into etiology, monitoring, and treatment.

We define our patient target group as patients with KH without a known clinical metabolic or hormonal etiology. This is to differentiate KHI from patient organizations for GSD, growth hormone deficiency and adrenal insufficiency, even though members of these groups may also experience KH symptoms. KHI welcomes all patients who suffer from KH in our support group, where we will assist them in connecting with other disease specific support organizations.

**Which challenges are we facing?**

Current literature provides a broad, unclear etiology and pathophysiology of IKH, thereby limiting the scope of understanding especially the more severely affected patients. The KHI support group has the impression that pathological KH may often be underdiagnosed and inappropriately treated. For those with pathological KH there is the lack of support for both the patients and their primary caregivers. Rare diseases often come with additional stress to the family unit, as advocacy, research, and support falls on the patient and family members. It has been shown that in the case of a rare disease diagnosis, oftentimes the parent or caregiver will have a better understanding of the disease process than the healthcare team providing care for the patient. Limited access to services and government support, fragmented communication, and minimal experts in the field result in the need for family to step in as a patient medical navigator and advocate [61].

Advocating for a child without a diagnosis can become overwhelming to the family as social support dwindles and health care management becomes convoluted. The initial screening for KH is not standardized in many institutions, and when a diagnosis of IKH is made, parents have reported feelings that providers had offered minimal education and instruction on management. This results in families navigating uncharted territory with episodes of KH, hospitalizations, pushback from schools regarding symptom management and prevention plans, etc., while being explained that KH does not meet the definitions of a rare disease and therefore may not qualify for extra services.

KHI recognizes that pathological KH, as with many health conditions, is not only affecting the child, but creating daily challenges for the families and caregivers. The most significant of these challenges is the fear of hypoglycemic episodes that can lead to a range of complications and can have devastating consequences.

**What do we do?**

KHI aims to globally unite leading hypoglycemia experts with patients, caregivers, and healthcare providers, and to establish a greater understanding of IKH in the hopes to facilitate improved treatment options and greater quality of life for individuals suffering from KH.

KHI was launched on a variety of social media platforms in January 2020 in an effort to connect with families from across the globe. The interest from families affected by KH was significant. We found that the majority of the families were affected by IKH and had been left in limbo with no recognized specialists to reach and no patient organization. The Facebook page for KHI, https://www.facebook.com/ketotichypoglycemiainternational/,
has been exceptionally successful, leading to the formation of a Facebook group with more than 900 families thus far.

This is the first time these families have been able to enter into a support network of like-minded peers to share the daily difficulties presented with this condition, as well as offer and receive empathy and advice. We are committed to support and advocate for those in the KH community through our international KHI Parents Support Group by utilizing the contributions of general medical guidance made by our scientific advisory board, supporting research in the general well-being of KH-families, and furthering research into KH etiology, diagnosis, and management.

The organization aims to challenge current perceptions and attitudes to expand the recognition that IKH is more than a normal variation, and establish an international platform for future research collaboration. KHI strives to prevent IKH families from feeling silenced and underserved, as seen in other rare disease families [62]. KHI continues to bridge the gaps between doctors, families, providers, research, and awareness.

KHI strives to be recognized not only as a symptom-union, but as a rare disease partner, supporting research towards better understanding of the multifactorial causes of IKH and the genetic complexities of the numerous rare diseases it is associated with. All patients with KH share many of the same challenges, which is why collaboration with other rare disease patient organizations is of high priority.

Conclusion

IKH is a clinically heterogeneous disorder including physiological KH and pathological KH. Pathological KH affects the health and well-being of its patients and their families. IKH patients currently do not have known causative genetic mutations or metabolic disorders, but novel causes may emerge in future studies. In addition to unknown etiology, patients with pathological KH have limited access to support, family resources, and medical management recommendations. KHI was formed as a novel patient organization to enhance the understanding of IKH, attempting to bridge the gap between patients, families, providers, researchers, and support, ultimately to improve the management of IKH and thereby to increase the quality of life for patients living with KH.

References

1. Owen OE, Reichard GA Jr, Patel MS, Boden G. Energy metabolism in fasting and exercising. Adv Exp Med Biol. 1979;111:169–88.
2. White K, Truong L, Aaron K, Mushag N, Thornton PS. The incidence and etiology of previously undiagnosed hypoglycemic disorders in the emergency department. Pediatr Emerg Care. 2020;36(7):522–6.
3. Daly LP, Osterhoudt KC, Weinizer SA. Presenting features of idiopathic ketogenic hypoglycemia. J Emerg Med. 2003;25(1):39–43.
4. Pershad J, Monroe K, Atchison J. Childhood hypoglycemia in an urban emergency department: epidemiology and a diagnostic approach to the problem. Pediatr Emerg Care. 1998;14(4):268–71.
5. Köhler S, Carmody L, Vasilievsk N, Jacobsen JOB, Danis D, Gourdin JP, et al. Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources. Nucleic Acids Res. 2019;47(D1):D1018–27.
6. Shefchek KA, Harris NL, Gargano M, Matenzoglu N, Uninn D, Brush M, et al. The Monarch Initiative in 2019: an integrative data and analytic platform connecting phenotypes to genotypes across species. Nucleic Acids Res. 2020;48(D1):D704–15.
7. Colle E, Ulstrom RA. Ketotic hypoglycemia. J Pediatr. 1964;64:632–31.
8. Senior B. Ketotic hypoglycemia. A tale (tail) of Gauss? J Pediatr. 1973;82(3):555–6.
9. Bodamer OA, Hussein K, Morris AA, Langhans CD, Rating D, Mayatepek E, et al. Glucose and leucine kinetics in idiopathic ketogenic hypoglycemia. Arch Dis Child. 2006;91(6):483–6.
10. Sprague JE, Arbeléez AM. Glucose counterregulatory responses to hypoglycemia. Pediatr Endocrinol Rev. 2011;9(1):463–73.
11. Gandhi K. Approach to hypoglycemia in infants and children. Transl Pediatr. 2017;6(4):408–20.
12. Ghosh A, Banerjee I, Morris AAM. Recognition, assessment and management of hypoglycaemia in childhood. Arch Dis Child. 2016;101(6):575–80.
13. Thornton PS, Stanley CA, De Leon DD, Harris D, Haymond MW, Hussain K, et al. Recommendations from the pediatric endocrine society for evaluation and management of persistent hypoglycemia in neonates, infants, and children. J Pediatr. 2015;167(2):238–45.
60. Ross KM, Brown LM, Corrado MM, Chengsupanimit T, Curry LM, Ferrecchia IA, et al. Safety and efficacy of chronic extended release cornstarch therapy for glycogen storage disease type I. JIMD Rep. 2016;26:85–90.

61. Currie G, Szabo J. “It is like a jungle gym, and everything is under construction”: the parent’s perspective of caring for a child with a rare disease. Child Care Health Dev. 2019;45(1):96–103.

62. Lopes MT, Koch VH, Sarrubbi-Junior V, Gallo PR, Carneiro-Sampaio M. Difficulties in the diagnosis and treatment of rare diseases according to the perceptions of patients, relatives and health care professionals. Clinics (Sao Paulo). 2018;73:e68.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.